Procurement managers operating in Sweden’s pharmaceutical sector face a demanding mix of strict regulation, high quality expectations and growing sustainability requirements. This practical guide breaks down the Swedish market context, regulatory responsibilities, procurement models, supplier selection and onboarding, quality and compliance (including GDP inspections), cold‑chain logistics and risk mitigation, and sustainability and cost‑to‑serve considerations — with tactical steps, checklists and KPIs you can apply immediately.

Swedish market context

Sweden’s pharmaceutical market is mature, with a strong presence of multinational manufacturers, specialized local players and significant public-sector purchasing. Growth drivers include an aging population and investments in biologics and advanced therapies. Country-level procurement is influenced by central reimbursement decisions and pricing frameworks that affect which products hospitals and clinics buy.

Practical implications: prioritize suppliers with proven Nordic experience and flexible pricing models that align with reimbursement requirements. For market and trend context, see an industry overview by IQVIA on Nordic opportunities and challenges IQVIA Nordic market brief and a sector outlook Sweden market report.

Regulatory landscape and procurement rules

Compliance begins with national regulators: the Swedish Medical Products Agency (Läkemedelsverket) oversees product safety and distribution authorizations, while the Dental and Pharmaceutical Benefits Agency (TLV) handles reimbursement and pricing processes that influence procurement decisions. Public purchasers must follow the Swedish Public Procurement Act and procurement guidance from Upphandlingsmyndigheten.

Actionable steps: map required licences and approvals for each product category; include contract clauses for changes driven by TLV decisions; and schedule regulatory status checks as part of supplier onboarding. Official resources: Läkemedelsverket general information Swedish Medical Products Agency, TLV guidance TLV (pricing and reimbursement), and procurement practice from the Swedish Public Procurement Agency Upphandlingsmyndigheten.

Procurement models and contracting

Common procurement models in Sweden include framework agreements for hospitals, tendered public contracts, and value‑based or managed‑entry agreements for high-cost therapies. Choose the model that balances supply security, price competitiveness and flexibility for demand variability.

Recommended tactical approach: for high-value biologics or new therapies use multi-year frameworks with performance clauses; for generics use competitive tenders with sustainability and continuity criteria. Build contract annexes for cold‑chain responsibilities, inspection access, and change control procedures.

Supplier selection, RFI/RFP and onboarding

Supplier selection should be evidence-driven, combining commercial, quality and sustainability due diligence. Use a structured RFI to screen capabilities and an RFP to evaluate price, service levels and compliance documentation.

1. RFP evaluation criteria (use weighted scoring): quality & regulatory compliance (30%), supply security & lead time (20%), total cost to serve (20%), cold‑chain capability (10%), sustainability practices (10%), financial stability (10%).

During onboarding, require submission of GDP certificates, sampling and stability data if relevant, a clear escalation matrix, and references from Nordic customers. Embed periodic reassessments into contracts (e.g., annual audits and KPI reviews).

Quality, compliance and GDP inspections

Sweden enforces Good Distribution Practice (GDP) to ensure integrity of medicines from warehouse to point of care. Procurement teams must verify supplier licences, distribution authorizations and inspection histories before awarding contracts.

Practical steps: verify the supplier’s MPA authorisation and recent inspection reports; include right‑to‑audit clauses; and require documented SOPs for cold‑chain handling, deviation management and batch traceability. For GDP details refer to guidance from the Swedish Medical Products Agency and European frameworks as needed.

Cold‑chain logistics and risk mitigation

Cold chain failures are a top risk for biologics and vaccines. Procurement must specify temperature ranges, monitoring requirements and contingency plans. Prefer partners with validated packaging, real‑time temperature monitoring and proven last‑mile capabilities in Sweden.

Risk mitigation tactics: use dual sourcing for critical SKUs, include buffer stock clauses, and run failure mode scenarios with logistics partners. Validate carriers against GDP criteria and require proof of cold‑chain performance during tender evaluation.

Sustainability and cost‑to‑serve

Swedish purchasers increasingly require sustainability metrics in procurement decisions. This includes lifecycle emissions, packaging waste reduction and socially responsible sourcing. Balance sustainability demands with cost‑to‑serve calculations to understand true total cost of ownership.

Suggested KPI set to measure procurement performance:

• Average lead time (days)
• Fill rate (%) — orders delivered complete
• Cost per order (SEK or EUR)
• Supplier on‑time delivery (%)
• Cold‑chain integrity incidents (count per year)
• Sustainability score (composite supplier metric)

Due diligence checklist for suppliers

Use this checklist before contract award to reduce compliance and supply risks.

• Valid distribution authorisation and licences
• Recent GDP inspection reports and corrective actions
• Documented cold‑chain SOPs and validation data
• Financial statements and business continuity plan
• References from Nordic customers or hospitals
• Evidence of sustainability policies and targets
• Insurance, indemnity and recall procedures

Common pitfalls to avoid

Avoid contracting solely on lowest price without assessing continuity risk, omitting GDP checks for logistics partners, and under‑specifying cold‑chain monitoring. Another common mistake is neglecting TLV reimbursement dynamics that can make a product commercially unviable despite a low purchase price.

Next steps and implementation checklist

Below is a short implementation checklist procurement managers can use to operationalise the guidance above. Use it to align stakeholders, run a pilot tender, and monitor supplier performance.

• Map regulatory and reimbursement status for target SKUs
• Run an RFI to shortlist suppliers with GDP and cold‑chain capability
• Issue RFP with weighted evaluation criteria and sustainability requirements
• Complete due diligence and request inspection reports
• Execute contracts with KPIs, audit rights and contingency clauses
• Review supplier KPIs quarterly and update sourcing strategy

For practical templates, sample RFP sections and supplier evaluation support, contact Pharma Procurement at info@pharmaprocurement.com, or run an initial supplier risk assessment using our CRO cost and capability calculator: CRO calculator. For direct support, reach out via WhatsApp +34 689 28 20 71.

References and further reading

• Swedish Medical Products Agency (Läkemedelsverket) — official site
• TLV — Dental and Pharmaceutical Benefits Agency
• Upphandlingsmyndigheten — Swedish Public Procurement Agency
• IQVIA — Key opportunities and challenges in the Nordic pharmaceutical market (2024)
• Grand View Research — Sweden pharmaceutical market outlook